{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:15:27Z","timestamp":1792131327179,"version":"4.4.0"},"reference-count":206,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lung cancer is currently the most prevalent malignancy and the leading cause of cancer deaths worldwide. Although the early stage non-small cell lung cancer (NSCLC) presents a relatively good prognosis, a considerable number of lung cancer cases are still detected and diagnosed at locally advanced or late stages. Surgical treatment combined with perioperative multimodality treatment is the mainstay of treatment for locally advanced NSCLC and has been shown to improve patient survival. Following the standard methods of neoadjuvant therapy, perioperative management, postoperative adjuvant therapy, and other therapeutic strategies are important for improving patients\u2019 prognosis and quality of life. However, controversies remain over the perioperative management of NSCLC and presently consensus and standardized guidelines are lacking for addressing critical clinical issues in multimodality treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The working group consisted of 125 multidisciplinary experts from thoracic surgery, medical oncology, radiotherapy, epidemiology, and psychology. This guideline was developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The clinical questions were collected and selected based on preliminary open-ended questionnaires and subsequent discussions during the Guideline Working Group meetings. PubMed, Web of Science, Cochrane Library, Scopus, and China National Knowledge Infrastructure (CNKI) were searched for available evidence. The GRADE system was used to evaluate the quality of evidence and grade the strengths of recommendations. Finally, the recommendations were developed through a structured consensus-building process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The Guideline Development Group initially collected a total of 62 important clinical questions. After a series of consensus-building conferences, 24 clinical questions were identified and corresponding recommendations were ultimately developed, focusing on neoadjuvant therapy, perioperative management, adjuvant therapy, postoperative psychological rehabilitation, prognosis assement, and follow-up protocols for NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This guideline puts forward reasonable recommendations focusing on neoadjuvant therapy, perioperative management, adjuvant therapy, postoperative psychological rehabilitation, prognosis assessment, and follow-up protocol of NSCLC. It standardizes perioperative multimodality treatment and provides guidance for clinical practice among thoracic surgeons, medical oncologists, and radiotherapists, aiming to reduce postoperative recurrence, improve patient survival, accelerate recovery, and minimize postoperative complications such as atelectasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003635","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T22:00:06Z","timestamp":1744927206000},"page":"2702-2721","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Clinical practice guidelines for perioperative multimodality treatment of non-small cell lung cancer"],"prefix":"10.1097","volume":"138","author":[{"given":"Wenjie","family":"Jiao","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[{"name":"CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Psychological Health Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvhua","family":"Wang","sequence":"additional","affiliation":[{"name":"National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[{"name":"CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunxu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugeng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Chinese Medical Journal Guideline Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"R1-20260303","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260303","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"R3-20260303","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R4-20260303","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20260303","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R6-20260303","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2018.02.008","article-title":"Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society)","volume":"118","author":"Cou\u00f1ago","year":"2018","journal-title":"Lung Cancer"},{"key":"R7-20260303","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2017.11.020","article-title":"Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer","volume":"115","author":"Lee","year":"2018","journal-title":"Lung Cancer"},{"key":"R8-20260303","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"R9-20260303","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-20260303","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"R11-20260303","first-page":"1","article-title":"Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy","volume":"42","author":"Provencio","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R12-20260303","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"R13-20260303","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group","volume":"311","year":"1995","journal-title":"BMJ"},{"key":"R14-20260303","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"},{"key":"R15-20260303","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41392-022-01286-3","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial","volume":"8","author":"Zhong","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R16-20260303","article-title":"Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials","volume":"10","author":"Sun","year":"2020","journal-title":"Front Oncol"},{"key":"R17-20260303","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00228-024-03620-w","article-title":"Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis","volume":"80","author":"Yu","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R18-20260303","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-015-0151-3","article-title":"Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status","volume":"8","author":"Zhong","year":"2015","journal-title":"J Hematol Oncol"},{"key":"R19-20260303","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7080","article-title":"East Asian patients who received immunotherapy-based therapy associated with improved survival benefit in advanced non-small cell lung cancer: An updated meta-analysis","volume":"13","author":"Yao","year":"2024","journal-title":"Cancer Med"},{"key":"R20-20260303","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14737140.2022.2116005","article-title":"The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Abdelazeem","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"R21-20260303","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1002\/ijc.32366","article-title":"PD-(L)1 inhibitors vs. chemotherapy vs. their combination in front-line treatment for NSCLC: An indirect comparison","volume":"145","author":"Liang","year":"2019","journal-title":"Int J Cancer"},{"key":"R22-20260303","doi-asserted-by":"crossref","first-page":"167.e1","DOI":"10.1016\/j.gaceta.2017.03.008","article-title":"Marcos GRADE de la evidencia a la decisi\u00f3n (EtD): un enfoque sistem\u00e1tico y transparente para tomar decisiones sanitarias bien informadas. 2: Gu\u00edas de pr\u00e1ctica cl\u00ednica [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]","volume":"32","author":"Alonso-Coello","year":"2018","journal-title":"Gac Sanit"},{"key":"R23-20260303","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"R24-20260303","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"R25-20260303","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002207","article-title":"Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp)","volume":"14","author":"Vernooij","year":"2017","journal-title":"PLoS Med"},{"key":"R26-20260303","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(98)06341-7","article-title":"Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R27-20260303","doi-asserted-by":"crossref","first-page":"8435","DOI":"10.1038\/s41467-023-44195-x","article-title":"Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial","volume":"14","author":"Altorki","year":"2023","journal-title":"Nat Commun"},{"key":"R28-20260303","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jtcvs.2022.07.017","article-title":"Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial","volume":"165","author":"Lee","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R29-20260303","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small-cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"R30-20260303","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","article-title":"Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)","volume":"33","author":"Eberhardt","year":"2015","journal-title":"J Clin Oncol"},{"key":"R31-20260303","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2006.08.2826","article-title":"Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)","volume":"25","author":"Rusch","year":"2007","journal-title":"J Clin Oncol"},{"key":"R32-20260303","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2007.14.1911","article-title":"Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806","volume":"26","author":"Kunitoh","year":"2008","journal-title":"J Clin Oncol"},{"key":"R33-20260303","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1183\/09031936.00108205","article-title":"Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour","volume":"29","author":"Marra","year":"2007","journal-title":"Eur Respir J"},{"key":"R34-20260303","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/icvts\/ivv032","article-title":"Results of surgical resection after induction chemoradiation for Pancoast tumours \u2020","volume":"20","author":"Marulli","year":"2015","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R35-20260303","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1743-7563.2009.01265.x","article-title":"Induction concurrent chemoradiotherapy compared with induction radiotherapy for superior sulcus non-small cell lung cancer: a retrospective study","volume":"6","author":"Li","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"key":"R36-20260303","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/icvts\/ivw216","article-title":"Does induction chemoradiotherapy increase survival in patients with Pancoast tumour","volume":"23","author":"Buderi","year":"2016","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R37-20260303","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.athoracsur.2014.04.129","article-title":"Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220","volume":"98","author":"Kernstine","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"R38-20260303","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R39-20260303","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R40-20260303","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"R41-20260303","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"R42-20260303","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative Nivolumab in Resectable Lung Cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"R43-20260303","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"R44-20260303","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"R45-20260303","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"R46-20260303","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"R47-20260303","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R48-20260303","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"R49-20260303","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2021.01.018","article-title":"Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience","volume":"153","author":"Eichhorn","year":"2021","journal-title":"Lung Cancer"},{"key":"R50-20260303","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jtcvs.2021.02.099","article-title":"Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer","volume":"163","author":"Tong","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R51-20260303","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"R52-20260303","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J Clin Oncol"},{"key":"R53-20260303","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"R54-20260303","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"R55-20260303","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s10637-022-01324-5","article-title":"Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China","volume":"41","author":"Hou","year":"2023","journal-title":"Invest New Drugs"},{"key":"R56-20260303","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J Clin Oncol"},{"key":"R57-20260303","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jtho.2023.02.019","article-title":"Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial","volume":"18","author":"Zhao","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R58-20260303","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jtcvs.2024.02.006","article-title":"Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)","volume":"168","author":"Yang","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R59-20260303","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"R60-20260303","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"},{"key":"R61-20260303","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","article-title":"Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK\u00a0Rearrangement","volume":"14","author":"Zhang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R62-20260303","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.2011.39.4882","article-title":"Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer","volume":"30","author":"Schaake","year":"2012","journal-title":"J Clin Oncol"},{"key":"R63-20260303","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1200\/JCO.2009.22.3370","article-title":"Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer","volume":"27","author":"Lara-Guerra","year":"2009","journal-title":"J Clin Oncol"},{"key":"R64-20260303","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","article-title":"Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study","volume":"161","author":"Zhang","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R65-20260303","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519887275","article-title":"Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients","volume":"48","author":"Xiong","year":"2020","journal-title":"J Int Med Res"},{"key":"R66-20260303","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1634\/theoncologist.2018-0120","article-title":"Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study","volume":"24","author":"Xiong","year":"2019","journal-title":"Oncologist"},{"key":"R67-20260303","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1200\/JCO.2009.22.3370","article-title":"Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer","volume":"27","author":"Lara-Guerra","year":"2009","journal-title":"J Clin Oncol"},{"key":"R68-20260303","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"R69-20260303","doi-asserted-by":"crossref","first-page":"407","DOI":"10.21037\/atm.2018.10.06","article-title":"Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy","volume":"6","author":"Ning","year":"2018","journal-title":"Ann Transl Med"},{"key":"R70-20260303","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","article-title":"Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study","volume":"161","author":"Zhang","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R71-20260303","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1634\/theoncologist.2018-0120","article-title":"Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study","volume":"24","author":"Xiong","year":"2019","journal-title":"Oncologist"},{"key":"R72-20260303","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519887275","article-title":"Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients","volume":"48","author":"Xiong","year":"2020","journal-title":"J Int Med Res"},{"key":"R73-20260303","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","article-title":"Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK\u00a0Rearrangement","volume":"14","author":"Zhang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R74-20260303","doi-asserted-by":"crossref","first-page":"73","DOI":"10.23736\/S1973-9087.19.05781-2","article-title":"Preoperative respiratory muscle endurance training improves ventilatory capacity and prevents pulmonary postoperative complications after lung surgery","volume":"56","author":"Laurent","year":"2020","journal-title":"Eur J Phys Rehabil Med"},{"key":"R75-20260303","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/1759-7714.14225","article-title":"Effect of physical manipulation pulmonary rehabilitation on lung cancer patients after thoracoscopic lobectomy","volume":"13","author":"Zhou","year":"2022","journal-title":"Thorac Cancer"},{"key":"R76-20260303","article-title":"Clinical Indicators of Effects of Yoga Breathing Exercises on Patients With Lung Cancer After Surgical Resection: A Randomized Controlled Trial","author":"Lu","year":"2023","journal-title":"Cancer Nurs"},{"key":"R77-20260303","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.23736\/S1973-9087.21.06789-7","article-title":"Rehabilitation for lung cancer patients undergoing surgery: results of the PUREAIR randomized trial","volume":"57","author":"Tenconi","year":"2021","journal-title":"Eur J Phys Rehabil Med"},{"key":"R78-20260303","first-page":"834","article-title":"Effect of continuous breathing exercise on self-care awareness and quality of life in patients after lung cancer surgery (in Chinese)","volume":"19","author":"Feng","year":"2022","journal-title":"Laboratory Medicine and Clinic"},{"key":"R79-20260303","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.athoracsur.2015.02.076","article-title":"Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer","volume":"100","author":"Berry","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"R80-20260303","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jtcvs.2021.12.030","article-title":"Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer","volume":"164","author":"Connolly","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R81-20260303","first-page":"236","article-title":"Effectiveness of multimodal functional rehabilitation training in patients with NSCLC undergoing surgical treatment (in Chinese)","volume":"17","author":"Yang","year":"2019","journal-title":"Contemporary Medical Symposium"},{"key":"R82-20260303","first-page":"85","article-title":"Effectiveness of perioperative multimodal rehabilitation training in patients with non-small cell lung cancer undergoing video-assisted thoracoscopic lobectomy (in Chinese)","volume":"29","author":"Du","year":"2023","journal-title":"Henan Journal of Surgery"},{"key":"R83-20260303","article-title":"Effect of lidocaine cream analgesia for chest drain tube removal after video-assisted thoracoscopic surgery for lung cancer: a randomized clinical trial","author":"Watanabe","year":"2019","journal-title":"Reg Anesth Pain Med"},{"key":"R84-20260303","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ejcts\/ezv097","article-title":"Efficacy of wound analgesia for controlling post-thoracotomy pain: a randomized double-blind study","volume":"49","author":"Fiorelli","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"R85-20260303","first-page":"34","article-title":"Effect of flurbiprofen axetil injection with preemptive analgesia on analgesia, inflammatory response, stress response and immune response in patients undergoing thoracoscopic lobectomy (in Chinese)","volume":"28","author":"Yao","year":"2019","journal-title":"Journal of Logistics University of PAP (Medical Sciences)"},{"issue":"Suppl 1","key":"R86-20260303","doi-asserted-by":"crossref","first-page":"i88","DOI":"10.1093\/bja\/aeu192","article-title":"Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis","volume":"113","author":"Maher","year":"2014","journal-title":"Br J Anaesth"},{"key":"R87-20260303","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181672","article-title":"Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery","volume":"12","author":"Oh","year":"2017","journal-title":"PLoS One"},{"key":"R88-20260303","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027618","article-title":"Effects of epidural analgesia on cancer recurrence and long-term mortality in patients after non-small-cell lung cancer resection: a propensity score-matched study","volume":"9","author":"Wu","year":"2019","journal-title":"BMJ Open"},{"key":"R89-20260303","doi-asserted-by":"crossref","first-page":"188","DOI":"10.21037\/tlcr-22-56","article-title":"Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer","volume":"11","author":"Dai","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"R90-20260303","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s12957-023-03247-8","article-title":"The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer","volume":"21","author":"Cai","year":"2023","journal-title":"World J Surg Oncol"},{"key":"R91-20260303","article-title":"Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery","volume":"2015","author":"Di Nisio","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R92-20260303","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.thromres.2017.03.024","article-title":"Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer","volume":"154","author":"Fuentes","year":"2017","journal-title":"Thromb Res"},{"key":"R93-20260303","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaoncol.2023.3634","article-title":"Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial","volume":"9","author":"Alexander","year":"2023","journal-title":"JAMA Oncol"},{"key":"R94-20260303","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1053\/j.semtcvs.2021.02.032","article-title":"Double Blind Pilot Randomized Trial Comparing Extended Anticoagulation to Placebo Following Major Lung Resection for Cancer","volume":"33","author":"Shargall","year":"2021","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"R95-20260303","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12893-021-01244-w","article-title":"Safety profile of preoperative administration of low-molecular-weight heparin on minimally invasive lung cancer surgery: a randomized controlled trial","volume":"21","author":"A-Lai","year":"2021","journal-title":"BMC Surg"},{"key":"R96-20260303","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"key":"R97-20260303","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/ajh.26945","article-title":"Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial","volume":"98","author":"Zhao","year":"2023","journal-title":"Am J Hematol"},{"key":"R98-20260303","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.21037\/jtd.2019.07.07","article-title":"Effectiveness of intraoperative administration of intermittent pneumatic compression in preventing deep vein thrombosis in lung cancer patients undergoing video-assisted thoracoscopic surgery lobectomy","volume":"11","author":"Wang","year":"2019","journal-title":"J Thorac Dis"},{"key":"R99-20260303","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12959-023-00498-z","article-title":"Postoperative intermittent pneumatic compression for preventing venous thromboembolism in Chinese lung cancer patients: a randomized clinical trial","volume":"21","author":"Li","year":"2023","journal-title":"Thromb J"},{"key":"R100-20260303","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.21037\/jtd.2018.03.13","article-title":"Effect of low molecular weight heparin on venous thromboembolism disease in thoracotomy patients with cancer","volume":"10","author":"Dong","year":"2018","journal-title":"J Thorac Dis"},{"key":"R101-20260303","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00595-003-2636-x","article-title":"Intermittent pneumatic compression is effective in preventing symptomatic pulmonary embolism after thoracic surgery","volume":"34","author":"Nagahiro","year":"2004","journal-title":"Surg Today"},{"key":"R102-20260303","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.jtcvs.2022.06.016","article-title":"Should all patients receive extended thromboprophylaxis after resection of primary lung cancer","volume":"164","author":"Kho","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R103-20260303","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clnesp.2021.12.026","article-title":"Associations between pretreatment nutritional assessments and treatment complications in patients with stage I-III non-small cell lung cancer: A systematic review","volume":"47","author":"Voorn","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"R104-20260303","first-page":"5597","article-title":"Effects of preoperative nutrition and multimodal prehabilitation on functional capacity and postoperative complications in surgical lung cancer patients: a systematic review","volume":"29","author":"Ferreira","year":"2021","journal-title":"Support Care Cancer"},{"key":"R105-20260303","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0003-4975(00)02006-3","article-title":"The influence of nutritional status on complications after operations for lung cancer","volume":"71","author":"Jagoe","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"R106-20260303","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: Clinical Nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin Nutr"},{"key":"R107-20260303","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.clnu.2021.03.031","article-title":"ESPEN practical guideline: Clinical nutrition in surgery","volume":"40","author":"Weimann","year":"2021","journal-title":"Clin Nutr"},{"key":"R108-20260303","first-page":"624","article-title":"Chinese Society of Anesthesiology, Chinese Medical Association. Clinical Practice Guidelines for Enhanced Recovery after Surgery in China (2021)(in Chinese)","volume":"12","year":"2021","journal-title":"Med J PUMCH"},{"key":"R109-20260303","first-page":"897","article-title":"Chinese Expert Consensus on Perioperative Nutritional Support in Enhanced Recovery after Surgery (2019 edition)(in Chinese)","volume":"18","year":"2019","journal-title":"Chin J Dig Surg"},{"key":"R110-20260303","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ajcn\/84.3.475","article-title":"The underappreciated role of muscle in health and disease","volume":"84","author":"Wolfe","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"R111-20260303","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1017\/S0954422413000115","article-title":"Nutritional strategies to counteract muscle atrophy caused by disuse and to improve recovery","volume":"26","author":"Magne","year":"2013","journal-title":"Nutr Res Rev"},{"key":"R112-20260303","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1213\/ANE.0000000000004342","article-title":"Two-Week Multimodal Prehabilitation Program Improves Perioperative Functional Capability in Patients Undergoing Thoracoscopic Lobectomy for Lung Cancer: A Randomized Controlled Trial","volume":"131","author":"Liu","year":"2020","journal-title":"Anesth Analg"},{"key":"R113-20260303","first-page":"365","article-title":"The effect of perioperative immunonutritional support on nutritional and inflammatory status in patients undergoing lung cancer surgery: a prospective, randomized controlled study","volume":"31","author":"Gunsel-Yildirim","year":"2023","journal-title":"Support Care Cancer"},{"key":"R114-20260303","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13019-016-0407-1","article-title":"Is preoperative protein-rich nutrition effective on postoperative outcome in non-small cell lung cancer surgery? A prospective randomized study","volume":"11","author":"Kaya","year":"2016","journal-title":"J Cardiothorac Surg"},{"key":"R115-20260303","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/gut.46.6.813","article-title":"A randomised controlled trial evaluating the use of enteral nutritional supplements postoperatively in malnourished surgical patients","volume":"46","author":"Beattie","year":"2000","journal-title":"Gut"},{"key":"R116-20260303","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13019-023-02263-9","article-title":"Early ambulation and postoperative recovery of patients with lung cancer under thoracoscopic surgery-an observational study","volume":"18","author":"Ding","year":"2023","journal-title":"J Cardiothorac Surg"},{"key":"R117-20260303","doi-asserted-by":"crossref","DOI":"10.1111\/ijn.12994","article-title":"Feasibility, safety and outcomes of ambulation within 2 h postoperatively in patients with lung cancer undergoing thoracoscopic surgery","volume":"28","author":"Liu","year":"2022","journal-title":"Int J Nurs Pract"},{"key":"R118-20260303","doi-asserted-by":"crossref","first-page":"9732","DOI":"10.21037\/apm-21-2102","article-title":"Early enhanced recovery after lung surgery: early ambulation 1 hour after extubation","volume":"10","author":"Zhou","year":"2021","journal-title":"Ann Palliat Med"},{"key":"R119-20260303","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s13304-023-01617-1","article-title":"Effects of mobilization within the first 4 h following anatomical lung resection with thoracotomy","volume":"75","author":"Unaldi","year":"2023","journal-title":"Updates Surg"},{"key":"R120-20260303","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00268-020-05836-0","article-title":"Four Hours Postoperative Mobilization is Feasible After Thoracoscopic Anatomical Pulmonary Resection","volume":"45","author":"Nakada","year":"2021","journal-title":"World J Surg"},{"key":"R121-20260303","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1298\/ptr.E10277","article-title":"Early Ambulation Following Lung Resection Surgery: Impact on Short-term Outcomes in Patients with Lung Cancer","volume":"27","author":"Kurata","year":"2024","journal-title":"Phys Ther Res"},{"key":"R122-20260303","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5249\/jivr.v1i1.5","article-title":"Volume threshold for chest tube removal: a randomized controlled trial","volume":"1","author":"Hessami","year":"2009","journal-title":"J Inj Violence Res"},{"key":"R123-20260303","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1072-7515(02)01332-7","article-title":"When to remove a chest tube? A randomized study with subsequent prospective consecutive validation","volume":"195","author":"Younes","year":"2002","journal-title":"J Am Coll Surg"},{"key":"R124-20260303","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/icvts\/ivv115","article-title":"A prospective randomized, controlled trial deems a drainage of 300 ml\/day safe before removal of the last chest drain after video-assisted thoracoscopic surgery lobectomy","volume":"21","author":"Xie","year":"2015","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"R125-20260303","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtcvs.2007.08.066","article-title":"Results of a prospective algorithm to remove chest tubes after pulmonary resection with high output","volume":"135","author":"Cerfolio","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R126-20260303","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.athoracsur.2007.05.058","article-title":"Fast-tracking after video-assisted thoracoscopic surgery lobectomy, segmentectomy, and pneumonectomy","volume":"84","author":"McKenna","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R127-20260303","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ejcts.2010.08.002","article-title":"Early removal of the chest tube after complete video-assisted thoracoscopic lobectomies","volume":"39","author":"G\u00f6ttgens","year":"2011","journal-title":"Eur J Cardiothorac Surg"},{"key":"R128-20260303","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/ejcts\/ezt376","article-title":"Early chest tube removal after video-assisted thoracic surgery lobectomy with serous fluid production up to 500 ml\/day","volume":"45","author":"Bjerregaard","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"R129-20260303","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.athoracsur.2023.04.031","article-title":"Randomized Trial of Modified Chest Tube Placement vs Routine Placement After Lung Resection","volume":"116","author":"Yun","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"R130-20260303","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1200\/JCO.2015.61.1517","article-title":"Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer","volume":"33","author":"Wang","year":"2015","journal-title":"J Clin Oncol"},{"key":"R131-20260303","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.athoracsur.2014.09.033","article-title":"Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery","volume":"99","author":"Hancock","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"R132-20260303","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol"},{"key":"R133-20260303","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaoncol.2021.1910","article-title":"Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial","volume":"7","author":"Hui","year":"2021","journal-title":"JAMA Oncol"},{"key":"R134-20260303","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.2005.04.6110","article-title":"Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database","volume":"24","author":"Lally","year":"2006","journal-title":"J Clin Oncol"},{"key":"R135-20260303","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/JTO.0000000000000406","article-title":"Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database","volume":"10","author":"Corso","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R136-20260303","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2014.58.5380","article-title":"Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R137-20260303","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/cam4.2937","article-title":"Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study","volume":"9","author":"Wei","year":"2020","journal-title":"Cancer Med"},{"key":"R138-20260303","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.lungcan.2013.02.005","article-title":"A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell lung cancer","volume":"80","author":"Burdett","year":"2013","journal-title":"Lung Cancer"},{"key":"R139-20260303","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.680615","article-title":"Postoperative Radiotherapy for Patients With Resectable Stage III-N2 Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"11","author":"Lei","year":"2021","journal-title":"Front Oncol"},{"key":"R140-20260303","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jtcvs.2022.09.062","article-title":"Postoperative radiotherapy with modern techniques does not improve survival for operable stage IIIA-N2 non-small cell lung cancer","volume":"165","author":"Predina","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R141-20260303","doi-asserted-by":"crossref","first-page":"1178064","DOI":"10.3389\/fonc.2023.1178064","article-title":"The prognostic value of postoperative radiotherapy in right tumor for lung related death: based on SEER database and real-world data","volume":"13","author":"Mo","year":"2023","journal-title":"Front Oncol"},{"key":"R142-20260303","first-page":"64","article-title":"Propensity score-matching analysis of postoperative radiotherapy for patients with stage IIIA\/N2 non-small cell lung cancer(in Chinese)","volume":"8","author":"Wu","year":"2023","journal-title":"Journal of Dali University"},{"key":"R143-20260303","first-page":"321","article-title":"The exploration course of postoperative radiotherapy for stage III N2 non-small cell lung cancer (in Chinese)","volume":"20","author":"Liang","year":"2020","journal-title":"Journal of Evidence-Based Medicine"},{"key":"R144-20260303","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/j.cllc.2017.10.011","article-title":"Improved Survival With Increased Time-To-Radiation and Sequential Chemotherapy After Surgery for pN2 Non-Small-cell Lung Cancer","volume":"19","author":"Sura","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R145-20260303","doi-asserted-by":"crossref","first-page":"718","DOI":"10.6004\/jnccn.2020.7537","article-title":"Effects of Postoperative Radiotherapy on Survival of Patients With Stage IIIA Resected Non-Small Cell Lung Cancer: Analysis of the SEER Database","volume":"18","author":"Gao","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R146-20260303","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.2217\/fon-2018-0326","article-title":"Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis","volume":"14","author":"Kou","year":"2018","journal-title":"Future Oncol"},{"key":"R147-20260303","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.jtho.2018.08.2021","article-title":"Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach","volume":"13","author":"Deng","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R148-20260303","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/1759-7714.13835","article-title":"Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected IIIA\/N2 non-small cell lung cancer: A population-based study","volume":"12","author":"Xu","year":"2021","journal-title":"Thorac Cancer"},{"key":"R149-20260303","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1245\/s10434-020-09154-6","article-title":"Characterization of Extracapsular Lymph Node Involvement and Its Clinicopathological Characteristics in Stage II-IIIA Lung Adenocarcinoma","volume":"28","author":"Chen","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R150-20260303","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/5584_2018_238","article-title":"Prognostic Impact of Extracapsular Lymph Node Invasion on Survival in Non-small-Cell Lung Cancer: A Systematic Review and Meta-analysis","volume":"1116","author":"Tabatabaei","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R151-20260303","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<265::AID-CNCR10>3.0.CO;2-B","article-title":"A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d\u2019Etude et de Traitement des Cancers Bronchiques","volume":"86","author":"Dautzenberg","year":"1999","journal-title":"Cancer"},{"key":"R152-20260303","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"R153-20260303","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R154-20260303","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"R155-20260303","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"R156-20260303","first-page":"100621","article-title":"Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis","volume":"5","author":"Wang","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"R157-20260303","first-page":"31","article-title":"Expert consensus on icotinib as adjuvant therapy for non-small cell lung cancer (in Chinese)","volume":"45","year":"2023","journal-title":"Chin J Oncol"},{"key":"R158-20260303","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R159-20260303","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.21037\/tlcr-21-557","article-title":"Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature","volume":"10","author":"Desage","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"R160-20260303","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"R161-20260303","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"R162-20260303","first-page":"11","article-title":"Comments on CSCO management guideline of toxicities from immune checkpoint inhibitors: comparing with NCCN guideline (in Chinese)","volume":"35","author":"Zhao","year":"2020","journal-title":"J Pract Oncol"},{"key":"R163-20260303","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"R164-20260303","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R165-20260303","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41392-023-01700-4","article-title":"Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R166-20260303","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"R167-20260303","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol"},{"key":"R168-20260303","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"R169-20260303","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"R170-20260303","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jtho.2023.05.015","article-title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial","volume":"18","author":"John","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R171-20260303","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"key":"R172-20260303","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R173-20260303","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.21037\/tlcr-20-1214","article-title":"Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study","volume":"9","author":"Zeng","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R174-20260303","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.cllc.2018.05.007","article-title":"Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A\u00a0Single-Center Retrospective Study","volume":"19","author":"Xie","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R175-20260303","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With\u00a0Osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncol"},{"key":"R176-20260303","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/OP.22.00787","article-title":"Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer","volume":"19","author":"Singh","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"R177-20260303","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1097\/CM9.0000000000001819","article-title":"Impact of thymosin \u03b11 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis","volume":"134","author":"Guo","year":"2021","journal-title":"Chin Med J"},{"key":"R178-20260303","first-page":"327","article-title":"Immunotherapy and changes in perioperative cellular immune function in patients with non-small cell lung cancer (in Chinese)","volume":"16","author":"Wei","year":"2016","journal-title":"Chinese Journal of Clinical Thoracic and Cardiovascular Surgery"},{"key":"R179-20260303","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jamasurg.2019.4526","article-title":"Practical Guide to Assessment of Patient-Reported Outcomes","volume":"155","author":"Davidson","year":"2020","journal-title":"JAMA Surg"},{"key":"R180-20260303","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cllc.2017.02.008","article-title":"Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer","volume":"18","author":"Morrison","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"R181-20260303","doi-asserted-by":"crossref","first-page":"101155","DOI":"10.1016\/j.esmoop.2023.101155","article-title":"Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline","volume":"8","author":"Grassi","year":"2023","journal-title":"ESMO Open"},{"key":"R182-20260303","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamasurg.2018.5093","article-title":"Association Between Postoperative Delirium and Long-term Cognitive Function After Major Nonemergent Surgery","volume":"154","author":"Austin","year":"2019","journal-title":"JAMA Surg"},{"key":"R183-20260303","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jclinepi.2015.02.011","article-title":"Summary scores captured changes in subjects\u2019 QoL as measured by the multiple scales of the EORTC QLQ-C30","volume":"68","author":"Phillips","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"R184-20260303","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1097\/JTO.0b013e31822b01a1","article-title":"Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis","volume":"6","author":"Calman","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R185-20260303","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.athoracsur.2018.08.015","article-title":"Comparing Two Imaging Methods for Follow-Up of Lung Cancer Treatment: A Randomized Pilot Study","volume":"107","author":"Gambazzi","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R186-20260303","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jnci\/djac208","article-title":"Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer","volume":"115","author":"Heiden","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"R187-20260303","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2022.08.020","article-title":"Role of 18F-FDG PET\/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study","volume":"173","author":"Kaumanns","year":"2022","journal-title":"Lung Cancer"},{"key":"R188-20260303","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41416-024-02678-8","article-title":"Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study","volume":"130","author":"Li","year":"2024","journal-title":"Br J Cancer"},{"key":"R189-20260303","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jtcvs.2012.09.030","article-title":"Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance","volume":"145","author":"Lou","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R190-20260303","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/SLA.0000000000002955","article-title":"More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study","volume":"268","author":"McMurry","year":"2018","journal-title":"Ann Surg"},{"key":"R191-20260303","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezac549","article-title":"Postoperative surveillance using low-dose computed tomography for non-small-cell lung cancer","volume":"63","author":"Nakada","year":"2022","journal-title":"Eur J Cardiothorac Surg"},{"key":"R192-20260303","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jtcvs.2018.09.119","article-title":"Imaging Surveillance for Surgically Resected Stage I Non-Small Cell Lung Cancer: Is More Always Better?","volume":"157","author":"Subramanian","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R193-20260303","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(22)00451-X","article-title":"Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Westeel","year":"2022","journal-title":"Lancet Oncol"},{"key":"R194-20260303","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.athoracsur.2011.07.005","article-title":"Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer","volume":"92","author":"Choi","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"R195-20260303","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","article-title":"Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R196-20260303","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/1878-0261.13387","article-title":"Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study","volume":"17","author":"Fu","year":"2023","journal-title":"Mol Oncol"},{"key":"R197-20260303","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/1878-0261.13116","article-title":"Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer","volume":"16","author":"Waldeck","year":"2022","journal-title":"Mol Oncol"},{"key":"R198-20260303","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jtho.2023.05.027","article-title":"Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer","volume":"18","author":"Jung","year":"2023","journal-title":"J Thorac Oncol"},{"key":"R199-20260303","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.561598","article-title":"Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer","volume":"10","author":"Peng","year":"2020","journal-title":"Front Oncol"},{"key":"R200-20260303","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/cncr.33985","article-title":"Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer","volume":"128","author":"Li","year":"2022","journal-title":"Cancer"},{"key":"R201-20260303","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.21037\/tlcr-20-505","article-title":"Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study","volume":"9","author":"Ohara","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R202-20260303","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jtcvs.2024.01.017","article-title":"Early real-world experience monitoring circulating tumor DNA in resected early-stage non-small cell lung cancer","volume":"168","author":"Martin","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R203-20260303","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"R204-20260303","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/diagnostics10030144","article-title":"Circulating Tumor Cells as a Tool of Minimal Residual Disease Can Predict Lung Cancer Recurrence: A longitudinal, Prospective Trial","volume":"10","author":"Wu","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"R205-20260303","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov"},{"key":"R206-20260303","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.21037\/tlcr-22-390","article-title":"Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review","volume":"11","author":"Verz\u00e8","year":"2022","journal-title":"Transl Lung Cancer Res"}],"updated-by":[{"DOI":"10.1097\/cm9.0000000000003979","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000}},{"DOI":"10.1097\/cm9.0000000000003979","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000}}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T19:01:40Z","timestamp":1772564500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":206,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003635","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"2025-01-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}